Small bowel bacterial overgrowth: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett (New page: <ref name="titleMedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth">{{cite web |url=http://www.nlm.nih.gov/medlineplus/ency/article/000222.htm |title=MedlinePlus Medical En...) |
mNo edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
<ref name="titleMedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth">{{cite web |url=http://www.nlm.nih.gov/medlineplus/ency/article/000222.htm |title=MedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth |accessdate=2008-01-04 |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> | {{subpages}} | ||
'''Small bowel bacterial overgrowth''' is a syndrome of lower gastrointestinal symptoms that occurs in the settings such as gastrointestinal anatomic abnormalities (such as surgically created blind loops) or abnormal small intestinal motility (diabetic neuropathy).<ref name="titleMedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth">{{cite web |url=http://www.nlm.nih.gov/medlineplus/ency/article/000222.htm |title=MedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth |accessdate=2008-01-04 |author= |authorlink= |coauthors= |date= |format= |work= |publisher= |pages= |language= |archiveurl= |archivedate= |quote=}}</ref> | |||
==Small bowel bacterial overgrowth and Irritable bowel syndrome== | |||
More controversial is the connection between bacterial overgrowth and [[irritable bowel syndrome]].<ref name="pmid17043344">{{cite journal |author=Drossman DA |title=Treatment for bacterial overgrowth in the irritable bowel syndrome |journal=Ann. Intern. Med. |volume=145 |issue=8 |pages=626–8 |year=2006 |pmid=17043344 |doi=|url=http://www.annals.org/cgi/content/full/145/8/626}}</ref> | |||
<ref name="pmid15316000">{{cite journal |author=Lin HC |title=Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome |journal=JAMA |volume=292 |issue=7 |pages=852–8 |year=2004 |pmid=15316000 |doi=10.1001/jama.292.7.852}}</ref> Between 10% and 80% of patients with [[irritable bowel syndrome]] have bacterial overgrowth as detected by the lactulose H<sub>2</sub> breath test.<ref name="pmid17043344"/> However, the accuracy of the lactulose H<sub>2</sub> breath test is disputed.<ref name="pmid17043344"/> | |||
The intestine is colonised with bacteria (also termed the gut flora). In studies from the one research group found that 78% to 84% of patients with IBS had bacterial overgrowth. In patients with evidence of bacterial overgrowth, those treated with [[neomycin]] had a >/= 35% reduction in clinical response (ie, improvement) compared with an 11% reduction in patients on placebo.<ref name="AmJGastro2000-Pimentel">{{cite journal | author=Pimentel M, Chow EJ, Lin HC | title=Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome | journal=Am J Gastroenterol | year=2000 | pages=3503–6 | volume=95 | issue=12 | id=PMID 11151884}}</ref><ref name="AmJGastro2003-Pimentel"> {{cite journal | author=Pimentel M, Chow EJ, Lin HC | title=Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study | journal=Am J Gastroenterol | year=2003 | pages=412–9 | volume=98 | issue=2 | id=PMID 12591062}}</ref> | |||
[[Rifaximin]], a nonabsorbed oral [[antibiotic]] improved some symptoms in a randomized controlled trial of patients with [[irritable bowel syndrome]].<ref name="pmid17043337">{{cite journal |author=Pimentel M, Park S, Mirocha J, Kane SV, Kong Y |title=The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial |journal=Ann. Intern. Med. |volume=145 |issue=8 |pages=557–63 |year=2006 |pmid=17043337 |doi=|url=http://www.annals.org/cgi/content/full/145/8/557}}</ref> | |||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
[[Category: | |||
Latest revision as of 06:01, 19 October 2024
Small bowel bacterial overgrowth is a syndrome of lower gastrointestinal symptoms that occurs in the settings such as gastrointestinal anatomic abnormalities (such as surgically created blind loops) or abnormal small intestinal motility (diabetic neuropathy).[1]
Small bowel bacterial overgrowth and Irritable bowel syndrome
More controversial is the connection between bacterial overgrowth and irritable bowel syndrome.[2] [3] Between 10% and 80% of patients with irritable bowel syndrome have bacterial overgrowth as detected by the lactulose H2 breath test.[2] However, the accuracy of the lactulose H2 breath test is disputed.[2]
The intestine is colonised with bacteria (also termed the gut flora). In studies from the one research group found that 78% to 84% of patients with IBS had bacterial overgrowth. In patients with evidence of bacterial overgrowth, those treated with neomycin had a >/= 35% reduction in clinical response (ie, improvement) compared with an 11% reduction in patients on placebo.[4][5]
Rifaximin, a nonabsorbed oral antibiotic improved some symptoms in a randomized controlled trial of patients with irritable bowel syndrome.[6]
References
- ↑ MedlinePlus Medical Encyclopedia: Small bowel bacterial overgrowth. Retrieved on 2008-01-04.
- ↑ 2.0 2.1 2.2 Drossman DA (2006). "Treatment for bacterial overgrowth in the irritable bowel syndrome". Ann. Intern. Med. 145 (8): 626–8. PMID 17043344. [e]
- ↑ Lin HC (2004). "Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome". JAMA 292 (7): 852–8. DOI:10.1001/jama.292.7.852. PMID 15316000. Research Blogging.
- ↑ Pimentel M, Chow EJ, Lin HC (2000). "Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome". Am J Gastroenterol 95 (12): 3503–6. PMID 11151884.
- ↑ Pimentel M, Chow EJ, Lin HC (2003). "Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study". Am J Gastroenterol 98 (2): 412–9. PMID 12591062.
- ↑ Pimentel M, Park S, Mirocha J, Kane SV, Kong Y (2006). "The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial". Ann. Intern. Med. 145 (8): 557–63. PMID 17043337. [e]